Monday, January 13, 2014

Biosensors -Is privatisation on the cards? (CIMB)

Biosensors Int'l
Current S$0.88
Target S$1.19
Is privatisation on the cards?

▊ Share price volatility and enlarged trading volume of late have caught the attention of many investors. It is now harder for earnings to make any meaningful impact in the next two quarters and its bombed-out valuation and change in ownership suggest that the stock is no longer well owned. We think that the new shareholder, CITIC, could seek to enhance its investment value through more active participation, potentially even taking the company private. We keep our EPS estimates and SOP-based target price. We also keep our contrarian Add rating, which hinges on the instant success of product launches, regulatory approvals and M&A accretion.

 
What Happened
After CITIC group backed CB Medical, took over from Shandong Weigao as the substantial shareholder (S$1.05/share for a 21.7% stake in BIG) in late Nov 13, BIG’s share price has seen unusual volatility on the back of rising liquidity.  
 
What We Think
Volatile share price movements aside, we reiterate our view that PE investors tend to explore various options where their companies have successful franchises but trade below market multiples. There could be a rethink about whether to keep BIG listed or, at a later stage, whether to relist BIG in another market, where there is better appreciation of a medical platform company. What can cash do? Based on the latest reported financials, BIG still has S$238m in net cash and, more importantly, US$512m in cash. Granted that a large part of US$274m in loans are from the MTN (US$240m at a 4.875% fixed rate due in 2017), BIG has yet to reach its ceiling of US$800m. Given that working capital needs are typically in the US$10m range, there is really not much need for cash at the moment. At its current share price, US$500m represents c.43% of BIG’s market cap. From a financing point of view, this means that both its PE investors are very capable of funding a privatisation deal on BIG, especially given the potential of upstreaming the cash hoard. The only unknowns then are, in the event of a take-out play, price and timing. (see page 2 - recent transactions of Chinese medical companies).  
 
What You Should Do
We urge investors to Add. BIG’s valuation has only priced in its near-term challenges, not a potential earnings lift from the commercialisation of new products in FY15. Other products are gaining ground with various regulatory authorities and a soft launch of BioFreedom remains a source of excitement.


Source/Extract/Excerpts/来源/转贴/摘录: CIMB-Research,
Publish date:07/01/13

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock